![]() ![]() In the interim, he began laying down a strong IP position in patents. With the advent of NVIDIA's GPU computing architectures, a suitable computing platform now exists. The company was a member of the Queensland Government's i.lab Incubator, a technology incubator for promising start-ups.Īt that time practical deployment of the Neuromathix algorithms had to be delayed until cheap, scalable massively-parallel computing platforms became available. In 2001, he founded NeuroTech Research Pty Ltd (NTR), which was awarded a Queensland Government Innovation Start-Up Scheme (ISUS) grant for the development of software to aid medication of a number of chronic diseases, leading to the Neuromathix software. He is one of Australia’s Spitfire Memorial Defence Fellows. A former senior analyst in the Australian Government, he is experienced in running research programmes in both public and private sectors. Holding first class honours in pure mathematics and a PhD in differential game theory, he is a former Honorary Senior Fellow of the School of Mathematics and Physics at the University of Queensland. Syntaxin is based near Oxford in the UK and has raised in excess of £22 million since late 2005 from top tier investors Abingworth, SR One, LSP, JJDC and Quest for Growth.Nigel is a mathematician and inventor of the Neuromathix technology and patents: new forms of evolutionary machine learning and adversarial AI, constructed using completely different mathematical approaches than neural networks, hence generating new machine learning and AI capabilities beyond neural networks. Syntaxin Ltd is a biotech company that designs and develops novel drugs for the treatment of cell secretion. He brings an impressive track record in business development particularly in innovative platform technologies and this will be of great benefit to the Company as we look to strengthen and expand our growing business development efforts.”įor more information on biopharmaceuticals or on Syntaxin’s work, visit ![]() ![]() Patrick Doyle, CEO of Syntaxin, said: “We are delighted to welcome Laurence to the Syntaxin team. He has an MSc in Biochemistry and Cellular & Molecular biology from the University of Auckland, New Zealand, a PhD in biochemistry and molecular biology from the Eberhard-Karls University of Tübingen, Germany, and an MBA from the Judge Business School, Cambridge University. Barker will assume responsibility for the implementation of the business development and commercial strategies surrounding the Syntaxin’s proprietary re-targeted endopeptidase discovery platform. Barker was Project Manager at Sympore GmbH, a private drug discovery company, where he led a multidisciplinary project team within research and early development of biopharmaceuticals.Īt Syntaxin, Dr. He was also a key member of the MorphoSys team that negotiated and signed the transformational strategic partnership with Novartis in 2007. In his previous position, Dr Barker led negotiations and completed several complex licensing deals and strategic collaborations with US, European and Japanese organisations, including those with the large Japanese pharmaceutical companies Daiichi-Sankyo, Astellas and Shionogi. 7, 2008 - PRLog - Oxford, UK - As Syntaxin have created this new role to initiate further business deals to aid the research and development of Syntaxin’s technology.
0 Comments
Leave a Reply. |